Oregon Health and Science University, Portland (United States of America)
Follow
Contributor content
Presentation
Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial
